$ENZN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ENZON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ENZON PHARMACEUTICALS, INC.. Get notifications about new insider transactions in ENZON PHARMACEUTICALS, INC. for free.
Page: < prev 1 2 3 4 5 6 6 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.30 | 85,903 | 798,898 | 39,147 | 125.1 K to 39.1 K (-68.69 %) |
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.30 | 8,720 | 81,133 | 125,050 | 133.8 K to 125.1 K (-6.52 %) |
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.31 | 100 | 931 | 133,770 | 133.9 K to 133.8 K (-0.07 %) |
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.32 | 1,600 | 14,912 | 133,870 | 135.5 K to 133.9 K (-1.18 %) |
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.32 | 300 | 2,796 | 135,470 | 135.8 K to 135.5 K (-0.22 %) |
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.33 | 4,406 | 41,108 | 135,770 | 140.2 K to 135.8 K (-3.14 %) |
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.33 | 100 | 933 | 140,176 | 140.3 K to 140.2 K (-0.07 %) |
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.34 | 200 | 1,867 | 140,276 | 140.5 K to 140.3 K (-0.14 %) |
Feb 26 2010 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec. VP Finance, C ... | Option Exercise | M | 6.97 | 50,000 | 348,500 | 0 | |
Feb 26 2010 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec. VP Finance, C ... | Option Exercise | M | 5.73 | 50,000 | 286,500 | 0 | |
Feb 26 2010 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec. VP Finance, C ... | Option Exercise | M | 6.95 | 50,000 | 347,500 | 0 | |
Feb 26 2010 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec. VP Finance, C ... | Sell | S | 9.27 | 150,000 | 1,390,635 | 128,096 | 278.1 K to 128.1 K (-53.94 %) |
Feb 26 2010 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec. VP Finance, C ... | Buy | M | 6.97 | 50,000 | 348,500 | 278,096 | 228.1 K to 278.1 K (+21.92 %) |
Feb 26 2010 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec. VP Finance, C ... | Buy | M | 5.73 | 50,000 | 286,500 | 228,096 | 178.1 K to 228.1 K (+28.07 %) |
Feb 26 2010 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec. VP Finance, C ... | Buy | M | 6.95 | 50,000 | 347,500 | 178,096 | 128.1 K to 178.1 K (+39.03 %) |
Jan 29 2010 | ENZN | ENZON PHARMACEUTIC ... | del Campo Ralph | EVP-Technical Opera ... | Grant | A | 0.00 | 12,665 | 0 | 148,122 | 135.5 K to 148.1 K (+9.35 %) |
Jan 29 2010 | ENZN | ENZON PHARMACEUTIC ... | Davit Paul Stephen | Exec. Vice Pres. HR | Grant | A | 0.00 | 7,559 | 0 | 82,524 | 75 K to 82.5 K (+10.08 %) |
Jan 29 2010 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Grant | A | 0.00 | 13,932 | 0 | 128,096 | 114.2 K to 128.1 K (+12.20 %) |
Jan 29 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP,R&D, CSO | Grant | A | 0.00 | 16,465 | 0 | 140,476 | 124 K to 140.5 K (+13.28 %) |
Jan 29 2010 | ENZN | ENZON PHARMACEUTIC ... | BUCHALTER JEFFREY H | CEO & President | Grant | A | 0.00 | 37,994 | 0 | 529,259 | 491.3 K to 529.3 K (+7.73 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Payment of Exercise | F | 10.91 | 10,053 | 109,678 | 124,011 | 134.1 K to 124 K (-7.50 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Buy | J | 0.00 | 8,333 | 0 | 134,064 | 125.7 K to 134.1 K (+6.63 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Buy | J | 0.00 | 18,333 | 0 | 134,064 | 115.7 K to 134.1 K (+15.84 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | del Campo Ralph | EVP-Technical Opera ... | Payment of Exercise | F | 10.91 | 10,053 | 109,678 | 135,457 | 145.5 K to 135.5 K (-6.91 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | del Campo Ralph | EVP-Technical Opera ... | Buy | J | 0.00 | 8,333 | 0 | 145,510 | 137.2 K to 145.5 K (+6.07 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | del Campo Ralph | EVP-Technical Opera ... | Buy | J | 0.00 | 18,333 | 0 | 145,510 | 127.2 K to 145.5 K (+14.42 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | Davit Paul Stephen | Exec. Vice Pres. HR | Payment of Exercise | F | 10.91 | 1,191 | 12,994 | 74,925 | 76.1 K to 74.9 K (-1.56 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | Davit Paul Stephen | Exec. Vice Pres. HR | Buy | J | 0.00 | 3,333 | 0 | 76,116 | 72.8 K to 76.1 K (+4.58 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | BUCHALTER JEFFREY H | CEO & President | Payment of Exercise | F | 10.91 | 39,391 | 429,756 | 491,265 | 530.7 K to 491.3 K (-7.42 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | BUCHALTER JEFFREY H | CEO & President | Buy | J | 0.00 | 33,333 | 0 | 530,656 | 497.3 K to 530.7 K (+6.70 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | BUCHALTER JEFFREY H | CEO & President | Buy | J | 0.00 | 66,666 | 0 | 530,656 | 464 K to 530.7 K (+14.37 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Payment of Exercise | F | 10.91 | 9,446 | 103,056 | 114,164 | 123.6 K to 114.2 K (-7.64 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Buy | J | 0.00 | 8,333 | 0 | 123,610 | 115.3 K to 123.6 K (+7.23 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Buy | J | 0.00 | 18,333 | 0 | 123,610 | 105.3 K to 123.6 K (+17.41 %) |
Jan 06 2010 | ENZN | ENZON PHARMACEUTIC ... | DENNER ALEXANDER J | Director | Option Exercise | A | 10.73 | 33,574 | 360,249 | 33,574 | |
Jan 06 2010 | ENZN | ENZON PHARMACEUTIC ... | Mulligan Richard | Director | Option Exercise | A | 10.73 | 16,787 | 180,125 | 16,787 | |
Jan 06 2010 | ENZN | ENZON PHARMACEUTIC ... | LEBUHN ROBERT | Director | Option Exercise | A | 10.73 | 16,787 | 180,125 | 16,787 | |
Jan 06 2010 | ENZN | ENZON PHARMACEUTIC ... | CLASSON ROLF A | Director | Option Exercise | A | 10.73 | 16,787 | 180,125 | 16,787 | |
Jan 06 2010 | ENZN | ENZON PHARMACEUTIC ... | SALISBURY ROBERT C | Director | Option Exercise | A | 10.73 | 16,787 | 180,125 | 16,787 | |
Jan 06 2010 | ENZN | ENZON PHARMACEUTIC ... | MICATI VICTOR P | Director | Option Exercise | A | 10.73 | 16,787 | 180,125 | 16,787 | |
Jan 06 2010 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Payment of Exercise | F | 10.77 | 4,157 | 44,771 | 123,610 | 127.8 K to 123.6 K (-3.25 %) |
Jan 06 2010 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Buy | J | 0.00 | 10,000 | 0 | 127,767 | 117.8 K to 127.8 K (+8.49 %) |
Dec 23 2009 | ENZN | ENZON PHARMACEUTIC ... | BUCHALTER JEFFREY H | CEO & President | Payment of Exercise | F | 10.77 | 10,635 | 114,539 | 530,656 | 541.3 K to 530.7 K (-1.96 %) |
Dec 23 2009 | ENZN | ENZON PHARMACEUTIC ... | BUCHALTER JEFFREY H | CEO & President | Buy | J | 0.00 | 30,000 | 0 | 541,291 | 511.3 K to 541.3 K (+5.87 %) |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Option Exercise | M | 0.00 | 3,000 | 0 | 4,000 | |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Payment of Exercise | F | 10.37 | 1,063 | 11,023 | 127,767 | 128.8 K to 127.8 K (-0.83 %) |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Buy | M | 0.00 | 3,000 | 0 | 128,830 | 125.8 K to 128.8 K (+2.38 %) |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | BUCHALTER JEFFREY H | Chairman, CEO & Pre ... | Option Exercise | M | 0.00 | 36,000 | 0 | 48,000 | |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | BUCHALTER JEFFREY H | Chairman, CEO & Pre ... | Payment of Exercise | F | 10.37 | 16,362 | 169,674 | 541,291 | 557.7 K to 541.3 K (-2.93 %) |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | BUCHALTER JEFFREY H | Chairman, CEO & Pre ... | Buy | M | 0.00 | 36,000 | 0 | 557,653 | 521.7 K to 557.7 K (+6.90 %) |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | Davit Paul Stephen | Exec. Vice Pres. HR | Option Exercise | M | 0.00 | 3,000 | 0 | 4,000 | |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | Davit Paul Stephen | Exec. Vice Pres. HR | Buy | M | 0.00 | 3,000 | 0 | 76,116 | 73.1 K to 76.1 K (+4.10 %) |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Option Exercise | M | 0.00 | 2,250 | 0 | 3,000 | |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Payment of Exercise | F | 10.37 | 797 | 8,265 | 134,064 | 134.9 K to 134.1 K (-0.59 %) |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Buy | M | 0.00 | 2,250 | 0 | 134,861 | 132.6 K to 134.9 K (+1.70 %) |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | del Campo Ralph | EVP-Technical Opera ... | Option Exercise | M | 0.00 | 3,000 | 0 | 4,000 | |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | del Campo Ralph | EVP-Technical Opera ... | Buy | M | 0.00 | 3,000 | 0 | 145,510 | 142.5 K to 145.5 K (+2.11 %) |
Sep 04 2009 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Option Exercise | M | 0.00 | 15,000 | 0 | 20,000 | |
Sep 04 2009 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Payment of Exercise | F | 7.58 | 5,313 | 40,273 | 132,611 | 137.9 K to 132.6 K (-3.85 %) |
Sep 04 2009 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Buy | M | 0.00 | 15,000 | 0 | 137,924 | 122.9 K to 137.9 K (+12.20 %) |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | SALISBURY ROBERT C | Director | Option Exercise | M | 0.00 | 1,106 | 0 | 0 | |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | SALISBURY ROBERT C | Director | Option Exercise | M | 0.00 | 3,173 | 0 | 3,173 | |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | SALISBURY ROBERT C | Director | Buy | M | 0.00 | 1,106 | 0 | 39,440 | 38.3 K to 39.4 K (+2.89 %) |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | SALISBURY ROBERT C | Director | Buy | M | 0.00 | 3,173 | 0 | 38,334 | 35.2 K to 38.3 K (+9.02 %) |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | LEBUHN ROBERT | Director | Option Exercise | M | 0.00 | 1,106 | 0 | 0 | |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | LEBUHN ROBERT | Director | Option Exercise | M | 0.00 | 3,173 | 0 | 3,173 | |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | LEBUHN ROBERT | Director | Buy | M | 0.00 | 1,106 | 0 | 106,303 | 105.2 K to 106.3 K (+1.05 %) |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | LEBUHN ROBERT | Director | Buy | M | 0.00 | 3,173 | 0 | 105,197 | 102 K to 105.2 K (+3.11 %) |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | MICATI VICTOR P | Director | Option Exercise | M | 0.00 | 1,106 | 0 | 0 | |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | MICATI VICTOR P | Director | Option Exercise | M | 0.00 | 3,173 | 0 | 3,173 | |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | MICATI VICTOR P | Director | Buy | M | 0.00 | 1,106 | 0 | 40,409 | 39.3 K to 40.4 K (+2.81 %) |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | MICATI VICTOR P | Director | Buy | M | 0.00 | 3,173 | 0 | 39,303 | 36.1 K to 39.3 K (+8.78 %) |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | CLASSON ROLF A | Director | Option Exercise | M | 0.00 | 1,106 | 0 | 0 | |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | CLASSON ROLF A | Director | Option Exercise | M | 0.00 | 3,173 | 0 | 3,173 | |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | CLASSON ROLF A | Director | Buy | M | 0.00 | 1,106 | 0 | 45,104 | 44 K to 45.1 K (+2.51 %) |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | CLASSON ROLF A | Director | Buy | M | 0.00 | 3,173 | 0 | 43,998 | 40.8 K to 44 K (+7.77 %) |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | ANDO GORAN | Director | Option Exercise | M | 0.00 | 1,106 | 0 | 0 | |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | ANDO GORAN | Director | Option Exercise | M | 0.00 | 3,173 | 0 | 3,173 | |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | ANDO GORAN | Director | Buy | M | 0.00 | 1,106 | 0 | 40,409 | 39.3 K to 40.4 K (+2.81 %) |
Jul 06 2009 | ENZN | ENZON PHARMACEUTIC ... | ANDO GORAN | Director | Buy | M | 0.00 | 3,173 | 0 | 39,303 | 36.1 K to 39.3 K (+8.78 %) |
May 26 2009 | ENZN | ENZON PHARMACEUTIC ... | Mulligan Richard | Director | Option Exercise | A | 7.19 | 25,889 | 186,142 | 25,889 | |
May 26 2009 | ENZN | ENZON PHARMACEUTIC ... | Mulligan Richard | Director | Grant | A | 0.00 | 10,432 | 0 | 10,432 | 0 to 10.4 K |
May 26 2009 | ENZN | ENZON PHARMACEUTIC ... | Denner Alexander J | Director | Option Exercise | A | 7.19 | 25,889 | 186,142 | 25,889 | |
May 26 2009 | ENZN | ENZON PHARMACEUTIC ... | Denner Alexander J | Director | Grant | A | 0.00 | 10,432 | 0 | 10,432 | 0 to 10.4 K |
May 14 2009 | ENZN | ENZON PHARMACEUTIC ... | del Campo Ralph | EVP, Technical Oper ... | Option Exercise | M | 0.00 | 4,500 | 0 | 6,000 | |
May 14 2009 | ENZN | ENZON PHARMACEUTIC ... | del Campo Ralph | EVP, Technical Oper ... | Payment of Exercise | F | 6.05 | 1,594 | 9,644 | 142,510 | 144.1 K to 142.5 K (-1.11 %) |
May 14 2009 | ENZN | ENZON PHARMACEUTIC ... | del Campo Ralph | EVP, Technical Oper ... | Buy | M | 0.00 | 4,500 | 0 | 144,104 | 139.6 K to 144.1 K (+3.22 %) |
May 14 2009 | ENZN | ENZON PHARMACEUTIC ... | Davit Paul Stephen | Exec. Vice Pres. HR | Option Exercise | M | 0.00 | 4,500 | 0 | 6,000 | |
May 14 2009 | ENZN | ENZON PHARMACEUTIC ... | Davit Paul Stephen | Exec. Vice Pres. HR | Buy | M | 0.00 | 4,500 | 0 | 73,116 | 68.6 K to 73.1 K (+6.56 %) |
May 14 2009 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Option Exercise | M | 0.00 | 4,500 | 0 | 6,000 | |
May 14 2009 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Payment of Exercise | F | 6.05 | 1,594 | 9,644 | 125,830 | 127.4 K to 125.8 K (-1.25 %) |
May 14 2009 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Buy | M | 0.00 | 4,500 | 0 | 127,424 | 122.9 K to 127.4 K (+3.66 %) |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Option Exercise | M | 0.00 | 16,740 | 0 | 39,060 | |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Sell | S | 6.12 | 5,930 | 36,292 | 122,924 | 128.9 K to 122.9 K (-4.60 %) |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Buy | M | 0.00 | 16,740 | 0 | 128,854 | 112.1 K to 128.9 K (+14.93 %) |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | del Campo Ralph | EVP, Technical Oper ... | Option Exercise | M | 0.00 | 12,600 | 0 | 29,400 | |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | del Campo Ralph | EVP, Technical Oper ... | Buy | M | 0.00 | 12,600 | 0 | 139,604 | 127 K to 139.6 K (+9.92 %) |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | Davit Paul Stephen | Exec. Vice Pres. HR | Option Exercise | M | 0.00 | 9,570 | 0 | 22,330 | |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | Davit Paul Stephen | Exec. Vice Pres. HR | Sell | S | 6.12 | 2,826 | 17,295 | 68,616 | 71.4 K to 68.6 K (-3.96 %) |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | Davit Paul Stephen | Exec. Vice Pres. HR | Buy | M | 0.00 | 9,570 | 0 | 71,442 | 61.9 K to 71.4 K (+15.47 %) |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Option Exercise | M | 0.00 | 19,860 | 0 | 46,340 | |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Sell | S | 6.12 | 7,035 | 43,054 | 122,924 | 130 K to 122.9 K (-5.41 %) |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Buy | M | 0.00 | 19,860 | 0 | 128,977 | 109.1 K to 129 K (+18.20 %) |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | BUCHALTER JEFFREY H | Chairman of the Boa ... | Option Exercise | M | 0.00 | 59,430 | 0 | 138,670 | |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | BUCHALTER JEFFREY H | Chairman of the Boa ... | Payment of Exercise | F | 6.12 | 27,011 | 165,307 | 521,653 | 548.7 K to 521.7 K (-4.92 %) |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | BUCHALTER JEFFREY H | Chairman of the Boa ... | Buy | M | 0.00 | 59,430 | 0 | 548,664 | 489.2 K to 548.7 K (+12.15 %) |
Jan 06 2009 | ENZN | ENZON PHARMACEUTIC ... | SALISBURY ROBERT C | Director | Option Exercise | A | 5.80 | 33,453 | 194,027 | 33,453 | |
Jan 21 2009 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Sell | S | 6.33 | 10,306 | 65,237 | 108,806 | 119.1 K to 108.8 K (-8.65 %) |
Jan 21 2009 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Buy | J | 0.00 | 18,334 | 0 | 119,112 | 100.8 K to 119.1 K (+18.19 %) |
Jan 21 2009 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Buy | J | 0.00 | 8,333 | 0 | 119,112 | 110.8 K to 119.1 K (+7.52 %) |
Jan 06 2009 | ENZN | ENZON PHARMACEUTIC ... | ANDO GORAN | Director | Option Exercise | A | 5.80 | 33,453 | 194,027 | 33,453 | |
Jan 06 2009 | ENZN | ENZON PHARMACEUTIC ... | Renfro Phillip M | Director | Option Exercise | A | 5.80 | 33,453 | 194,027 | 33,453 | |
Jan 06 2009 | ENZN | ENZON PHARMACEUTIC ... | Geltosky John | Director | Option Exercise | A | 5.80 | 33,453 | 194,027 | 33,453 | |
Jan 06 2009 | ENZN | ENZON PHARMACEUTIC ... | MICATI VICTOR P | Director | Option Exercise | A | 5.80 | 33,453 | 194,027 | 33,453 | |
Jan 06 2009 | ENZN | ENZON PHARMACEUTIC ... | LEBUHN ROBERT | Director | Option Exercise | A | 5.80 | 33,453 | 194,027 | 33,453 | |
Jan 06 2009 | ENZN | ENZON PHARMACEUTIC ... | CLASSON ROLF A | Director | Option Exercise | A | 5.80 | 33,453 | 194,027 | 33,453 | |
Nov 25 2008 | ENZN | ENZON PHARMACEUTIC ... | BUCHALTER JEFFREY H | Chairman, CEO & Pre ... | Option Exercise | M | 0.00 | 36,000 | 0 | 84,000 | |
Nov 25 2008 | ENZN | ENZON PHARMACEUTIC ... | BUCHALTER JEFFREY H | Chairman, CEO & Pre ... | Buy | M | 0.00 | 36,000 | 0 | 489,234 | 453.2 K to 489.2 K (+7.94 %) |
Nov 25 2008 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Option Exercise | M | 0.00 | 2,250 | 0 | 5,250 | |
Nov 25 2008 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Buy | M | 0.00 | 2,250 | 0 | 108,250 | 106 K to 108.3 K (+2.12 %) |
Nov 25 2008 | ENZN | ENZON PHARMACEUTIC ... | Davit Paul Stephen | Exec. Vice Pres. HR | Option Exercise | M | 0.00 | 3,000 | 0 | 7,000 | |
Nov 25 2008 | ENZN | ENZON PHARMACEUTIC ... | Davit Paul Stephen | Exec. Vice Pres. HR | Buy | M | 0.00 | 3,000 | 0 | 60,603 | 57.6 K to 60.6 K (+5.21 %) |
Nov 25 2008 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Option Exercise | M | 0.00 | 3,000 | 0 | 7,000 | |
Nov 25 2008 | ENZN | ENZON PHARMACEUTIC ... | TOOMAN CRAIG A | Exec VP Finance, CF ... | Buy | M | 0.00 | 3,000 | 0 | 119,122 | 116.1 K to 119.1 K (+2.58 %) |
Nov 25 2008 | ENZN | ENZON PHARMACEUTIC ... | del Campo Ralph | EVP - Technical Ope ... | Option Exercise | M | 0.00 | 3,000 | 0 | 7,000 | |
Nov 25 2008 | ENZN | ENZON PHARMACEUTIC ... | del Campo Ralph | EVP - Technical Ope ... | Buy | M | 0.00 | 3,000 | 0 | 124,156,136 | 124.2 M to 124.2 M (0.00 %) |
Nov 18 2008 | ENZN | ENZON PHARMACEUTIC ... | CLASSON ROLF A | Director | Buy | P | 4.07 | 5,500 | 22,385 | 15,961 | 10.5 K to 16 K (+52.58 %) |
Nov 18 2008 | ENZN | ENZON PHARMACEUTIC ... | CLASSON ROLF A | Director | Buy | P | 4.06 | 1,600 | 6,496 | 10,461 | 8.9 K to 10.5 K (+18.06 %) |
Nov 18 2008 | ENZN | ENZON PHARMACEUTIC ... | CLASSON ROLF A | Director | Buy | P | 4.05 | 300 | 1,215 | 8,861 | 8.6 K to 8.9 K (+3.50 %) |
Nov 18 2008 | ENZN | ENZON PHARMACEUTIC ... | CLASSON ROLF A | Director | Buy | P | 4.04 | 500 | 2,020 | 8,561 | 8.1 K to 8.6 K (+6.20 %) |
Nov 18 2008 | ENZN | ENZON PHARMACEUTIC ... | CLASSON ROLF A | Director | Buy | P | 4.03 | 400 | 1,612 | 8,061 | 7.7 K to 8.1 K (+5.22 %) |
Nov 18 2008 | ENZN | ENZON PHARMACEUTIC ... | CLASSON ROLF A | Director | Buy | P | 4.02 | 700 | 2,814 | 7,661 | 7 K to 7.7 K (+10.06 %) |
Nov 18 2008 | ENZN | ENZON PHARMACEUTIC ... | CLASSON ROLF A | Director | Buy | P | 4.01 | 1,000 | 4,010 | 6,961 | 6 K to 7 K (+16.78 %) |
Nov 17 2008 | ENZN | ENZON PHARMACEUTIC ... | ANDO GORAN | Director | Buy | P | 3.77 | 15,000 | 56,514 | 36,130 | 21.1 K to 36.1 K (+70.99 %) |
Nov 17 2008 | ENZN | ENZON PHARMACEUTIC ... | Renfro Phillip M | Director | Buy | P | 3.67 | 3,720 | 13,652 | 25,973 | 22.3 K to 26 K (+16.72 %) |
Nov 17 2008 | ENZN | ENZON PHARMACEUTIC ... | Renfro Phillip M | Director | Buy | P | 3.67 | 200 | 733 | 22,253 | 22.1 K to 22.3 K (+0.91 %) |
Nov 17 2008 | ENZN | ENZON PHARMACEUTIC ... | Renfro Phillip M | Director | Buy | P | 3.65 | 1,900 | 6,935 | 22,053 | 20.2 K to 22.1 K (+9.43 %) |
Nov 17 2008 | ENZN | ENZON PHARMACEUTIC ... | Renfro Phillip M | Director | Buy | P | 3.64 | 200 | 728 | 20,153 | 20 K to 20.2 K (+1.00 %) |
Nov 17 2008 | ENZN | ENZON PHARMACEUTIC ... | Renfro Phillip M | Director | Buy | P | 3.63 | 500 | 1,815 | 19,953 | 19.5 K to 20 K (+2.57 %) |
Nov 17 2008 | ENZN | ENZON PHARMACEUTIC ... | Renfro Phillip M | Director | Buy | P | 3.62 | 300 | 1,086 | 19,453 | 19.2 K to 19.5 K (+1.57 %) |
Nov 17 2008 | ENZN | ENZON PHARMACEUTIC ... | Renfro Phillip M | Director | Buy | P | 3.61 | 3,180 | 11,480 | 19,153 | 16 K to 19.2 K (+19.91 %) |
Nov 14 2008 | ENZN | ENZON PHARMACEUTIC ... | MICATI VICTOR P | Director | Buy | P | 3.28 | 15,000 | 49,271 | 36,130 | 21.1 K to 36.1 K (+70.99 %) |
Nov 14 2008 | ENZN | ENZON PHARMACEUTIC ... | SALISBURY ROBERT C | Director | Sell | P | 3.25 | 4,030 | 13,098 | 35,161 | 39.2 K to 35.2 K (-10.28 %) |
Nov 14 2008 | ENZN | ENZON PHARMACEUTIC ... | SALISBURY ROBERT C | Director | Buy | P | 3.24 | 100 | 324 | 31,131 | 31 K to 31.1 K (+0.32 %) |
Nov 14 2008 | ENZN | ENZON PHARMACEUTIC ... | SALISBURY ROBERT C | Director | Buy | P | 3.23 | 500 | 1,615 | 31,031 | 30.5 K to 31 K (+1.64 %) |
Nov 14 2008 | ENZN | ENZON PHARMACEUTIC ... | SALISBURY ROBERT C | Director | Buy | P | 3.21 | 1,897 | 6,089 | 30,531 | 28.6 K to 30.5 K (+6.62 %) |
Nov 14 2008 | ENZN | ENZON PHARMACEUTIC ... | SALISBURY ROBERT C | Director | Buy | P | 3.20 | 600 | 1,920 | 28,634 | 28 K to 28.6 K (+2.14 %) |
Nov 14 2008 | ENZN | ENZON PHARMACEUTIC ... | SALISBURY ROBERT C | Director | Buy | P | 3.19 | 2,873 | 9,165 | 28,034 | 25.2 K to 28 K (+11.42 %) |
Nov 13 2008 | ENZN | ENZON PHARMACEUTIC ... | BUCHALTER JEFFREY H | Chairman, CEO & Pre ... | Buy | P | 3.28 | 50,000 | 164,035 | 453,234 | 403.2 K to 453.2 K (+12.40 %) |
Sep 12 2008 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Option Exercise | M | 0.00 | 15,000 | 0 | 35,000 |